US Patent

US11478450 — Edaravone suspension for oral administration

Method of Use · Assigned to Mitsubishi Tanabe Pharma Corp · Expires 2039-11-01 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using edaravone for human oral administration.

USPTO Abstract

An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Drugs covered by this patent

Radicava (EDARAVONE) · Kk Bcj-94

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3468`	—	Radicava

Patent Metadata

Patent number: US11478450
Jurisdiction: US
Classification: Method of Use
Expires: 2039-11-01
Drug substance claim: No
Drug product claim: No
Assignee: Mitsubishi Tanabe Pharma Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.